MX2021013349A - Composicion para la prevencion o el tratamiento de la caida del cabello que incluye hapln1. - Google Patents

Composicion para la prevencion o el tratamiento de la caida del cabello que incluye hapln1.

Info

Publication number
MX2021013349A
MX2021013349A MX2021013349A MX2021013349A MX2021013349A MX 2021013349 A MX2021013349 A MX 2021013349A MX 2021013349 A MX2021013349 A MX 2021013349A MX 2021013349 A MX2021013349 A MX 2021013349A MX 2021013349 A MX2021013349 A MX 2021013349A
Authority
MX
Mexico
Prior art keywords
hapln1
composition
prevention
treatment
hair loss
Prior art date
Application number
MX2021013349A
Other languages
English (en)
Inventor
Dae Kyong Kim
Moon Jung Back
Ji Min Jang
Hae Chan Ha
In Chul Shin
Dan Zhou
Original Assignee
Haplnscience Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1020200051429A external-priority patent/KR102390418B1/ko
Application filed by Haplnscience Inc filed Critical Haplnscience Inc
Publication of MX2021013349A publication Critical patent/MX2021013349A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1741—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals alpha-Glycoproteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73—Polysaccharides
    • A61K8/735—Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q7/00—Preparations for affecting hair growth

Abstract

La presente invención se refiere a una composición farmacéutica para prevenir o tratar la caída del cabello, que comprende la proteína 1 de unión de hialuronano y proteoglucano (HAPLN1), como principio activo. Cuando se administra, la proteína HAPLN1 de la presente invención hace crecer el cabello al promover la proliferación de las células de la matriz germinal del cabello a través de una ruta de señalización Ras-ERK1/2 activada mediante una proteína TGF-ß.
MX2021013349A 2019-04-30 2020-04-29 Composicion para la prevencion o el tratamiento de la caida del cabello que incluye hapln1. MX2021013349A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20190050698 2019-04-30
KR1020200051429A KR102390418B1 (ko) 2019-04-30 2020-04-28 Hapln1을 포함하는 탈모 예방 또는 치료용 조성물
PCT/KR2020/005703 WO2020222538A2 (ko) 2019-04-30 2020-04-29 Hapln1을 포함하는 탈모 예방 또는 치료용 조성물

Publications (1)

Publication Number Publication Date
MX2021013349A true MX2021013349A (es) 2022-02-03

Family

ID=73028862

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021013349A MX2021013349A (es) 2019-04-30 2020-04-29 Composicion para la prevencion o el tratamiento de la caida del cabello que incluye hapln1.

Country Status (13)

Country Link
US (1) US20220202899A1 (es)
EP (1) EP3964223A4 (es)
JP (1) JP7182816B2 (es)
CN (1) CN113784723A (es)
AU (1) AU2020265476A1 (es)
BR (1) BR112021021860A2 (es)
CL (1) CL2021002853A1 (es)
IL (1) IL287659A (es)
MX (1) MX2021013349A (es)
PE (1) PE20220335A1 (es)
SG (1) SG11202112030SA (es)
WO (1) WO2020222538A2 (es)
ZA (1) ZA202109732B (es)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120128632A1 (en) 2009-07-23 2012-05-24 Jeffrey Keeler Teumer Identity markers
US8334136B2 (en) 2009-07-24 2012-12-18 Shiseido Company, Ltd. Method for promoting hair growth or hair regeneration by maintaining or increasing expression of cell-adhesion factor
JP6162707B2 (ja) * 2011-10-24 2017-07-12 ハロザイム インコーポレイテッド 抗ヒアルロナン剤治療のためのコンパニオン診断およびその使用方法
EP2859486A2 (en) * 2012-06-06 2015-04-15 The Procter & Gamble Company Systems and methods for identifying cosmetic agents for hair/scalp care compositions
KR101836029B1 (ko) * 2014-07-07 2018-03-08 메디포스트(주) 자극된 줄기세포 배양액의 발모 촉진능 및 이의 용도
KR101897340B1 (ko) * 2015-09-09 2018-09-13 중앙대학교 산학협력단 Hapln1을 이용한 피부 노화 측정 또는 예방 또는 개선용 조성물
KR101900748B1 (ko) * 2016-08-17 2018-09-20 (주)진셀팜 모발 성장 촉진 효과를 가지는 펩타이드, 및 이의 용도
WO2019045451A1 (ko) * 2017-08-29 2019-03-07 중앙대학교 산학협력단 Hapln1을 유효성분으로 함유하는 연골 재생용 조성물
KR20190024727A (ko) * 2017-08-29 2019-03-08 중앙대학교 산학협력단 Hapln1을 유효성분으로 함유하는 연골 재생용 조성물

Also Published As

Publication number Publication date
WO2020222538A2 (ko) 2020-11-05
CL2021002853A1 (es) 2022-06-17
JP7182816B2 (ja) 2022-12-05
BR112021021860A2 (pt) 2021-12-21
AU2020265476A1 (en) 2022-01-06
EP3964223A4 (en) 2023-01-18
JP2022530077A (ja) 2022-06-27
WO2020222538A9 (ko) 2021-02-25
CN113784723A (zh) 2021-12-10
IL287659A (en) 2021-12-01
SG11202112030SA (en) 2021-12-30
WO2020222538A3 (ko) 2021-01-14
EP3964223A2 (en) 2022-03-09
US20220202899A1 (en) 2022-06-30
PE20220335A1 (es) 2022-03-14
ZA202109732B (en) 2022-09-28

Similar Documents

Publication Publication Date Title
AU2018338608A1 (en) Methods, compositions, and implantable elements comprising active cells
CR20220316A (es) Tetrahidrofuranos sustituidos como moduladores de canales de sodio
PH12021550605A1 (en) Farnesoid x receptor agonists and uses thereof
TW200611695A (en) Pyrrolopyridine derivatives
EA200800798A1 (ru) Фармацевтические композиции, предназначенные для лечения нарушений внутреннего уха
MX2022007155A (es) Derivados de cromano novedosos que tienen actividad de degradacion de receptor de estrogeno y usos de los mismos.
BR112019001768A2 (pt) moduladores do receptor de spiro-lactamas nmda e usos dos mesmos
MX2022001874A (es) Receptores agonistas no peptidicos de somatostatina tipo 5 y usos de los mismos.
HRP20211824T1 (hr) Modulatori aktivnosti komplementa
MX2023003678A (es) Inhibidores de hidroxiesteroide 17beta- deshidrogenasa 13 (hsd17b13) y usos de estos.
MX2023003677A (es) Inhibidores de hidroxiesteroide 17beta- deshidrogenasa 13 (hsd17b13) y usos de estos.
MX2021013010A (es) Composiciones y metodos para modular la actividad del complemento.
EP4272832A3 (en) Antimicrobial compounds, compositions, and uses thereof
MX2022014925A (es) Moduladores de il-17a.
WO2022218941A3 (en) Compositions and methods for inhibiting ketohexokinase (khk)
MX2022000712A (es) Moduladores de nlrp3.
WO2015048188A3 (en) Modified fibroblast growth factors for the treatment of ocular disorders
MX2023003675A (es) Inhibidores de hidroxiesteroide 17beta-deshidrogenasa 13 (hsd17b13) y usos de estos.
MX2020006605A (es) Polisulfato de pentosano y medicamento que contiene polisulfato de pentosano.
CO2021013171A2 (es) Compuestos y composiciones como moduladores de la señalización de tlr
WO2019022482A3 (ko) 황칠나무 추출물을 유효성분으로 포함하는 섬유화 질환의 예방 또는 치료용 조성물
MX2021013349A (es) Composicion para la prevencion o el tratamiento de la caida del cabello que incluye hapln1.
MX2007002583A (es) Metodos y composiciones para realzar la degradacion de factores de transcripcion del receptor nuclear y sus usos.
MX2021008941A (es) Moduladores gpr35.
WO2019078663A3 (ko) 아연염, 시클로-히스프로 및 항당뇨 약물을 유효성분으로 함유하는 당뇨병 예방 또는 치료용 약학적 조성물